Analyst Tim Anderson of Bank of America Securities reiterated a Hold rating on Johnson & Johnson (JNJ – Research Report), reducing the ...
How is one of the world’s largest pharmaceutical companies promoting sustainability and regulatory compliance throughout its ...
This fall, pharmaceutical and medical technology company Johnson & Johnson announced that a newly created Dallas subsidiary ...
Johnson & Johnson (JNJ – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Lee ...
The institutional investor owned 43,167 shares of the company’s stock after purchasing an additional 2,058 shares during the period. Johnson & Johnson makes up approximately 1.6% of Ellsworth ...
Johnson & Johnson (NYSE:JNJ), a global healthcare giant, continues to navigate a complex landscape of opportunities and ...
Analysts discuss Johnson & Johnson's outlook, highlighting MedTech challenges, litigation risks, pipeline opportunities, and mixed performance across segments.
Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $168.85. The company has a fifty day moving average price of $148.35 and a two-hundred day moving average price of $156.11.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback